Navigation Links
Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
Date:9/13/2007

BIRMINGHAM, Ala., Sept. 13 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that it has licensed the rights to 4'-Thio-Ara-C, also known as SR9025, to Virium Pharmaceuticals, Inc. To date, six of Southern Research's anti-cancer drugs have received FDA approval and are on the market. Six others, including 4'-Thio-Ara-C, are in late stage preclinical testing or in early clinical trials.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 )

"Southern Research's agreement with Virium helps bring our work one step closer to the patients we hope to help. This is the first anti-cancer compound to be licensed after the completion of early clinical trials and we are eager to see it move through the pipeline," said John A. "Jack" Secrist, III, Ph.D., president and CEO of Southern Research. "We appreciate being able to work with a company when the success of our drug candidate is important to the success of the company."

The 4'-Thio-Ara-C compound, now registered to Virium as VP700, has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has already completed two phase I trials.

"Southern Research's prestigious cancer program and international track record are well known and respected in the industry. The opportunity to work with a compound designed and developed by researchers at Southern Research is very exciting," said James Pachence, Ph.D., Virium Pharmaceuticals president and CEO. "Our strategy is to focus on targets that play key roles in diseases, and which can potentially be exploited in multiple indications beyond oncology. In addition to VP700, we are currently developing a portfolio of chemistry-driven HDAC inhibitors for cancer."

Southern Research will receive cash and stock in Virium, and will hold seats on the Virium Pharmaceuticals Scientific Advisory Board and the Board of Directors. The technical seat will be filled by Dr. Secrist and the Board seat (non-voting) will be filled by Dr. Nancy M. Gray, vice president of Corporate Development at Southern Research.

ABOUT SOUTHERN RESEARCH

Southern Research is a not-for-profit organization that conducts scientific research at facilities in Alabama, Maryland, Missouri and North Carolina. Southern Research provides contract and basic research in the fields of preclinical drug discovery and development, advanced engineering, and environmental and energy-related research. For more information, see http://www.SouthernResearch.org.

ABOUT VIRIUM PHARMACEUTICALS

Virium Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics with an initial focus on cancer. Virium has its lead cancer product, VP101, in clinical trials in the United States. VP101 is an HDAC inhibitor being developed in collaboration with the National Cancer Institute of the NIH. For more information, visit http://www.viriumpharma.com.

Media Contact:

Rhonda Jung Risa Goldman Burgess

Southern Research Institute Schwartz Communications

205-581-2317 781-684-0770

Jung@southernresearch.org southern@schwartz-pr.com


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Minneapolis company sets sights on southern Wisconsin
2. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
3. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
4. Control Your siRNA Research
5. Getting Started with MicroRNA Research
6. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Research Organics
9. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. Research Tools for Analysis of ZAP-70
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... 6, 2016 The News Of Biomedical ... "Who Is Telling The Truth, Nature Or Man?" ... [1] The formal recognition of a fundamental omission ... published by a national academy of science with ... is a significant development towards the advancement of ...
(Date:5/6/2016)... , May 6, 2016 According to ... Molecular Diagnostic Market for Group A Streptococcus (GAS) Nucleic Acid ... Growth, Trends, and Forecast, 2015 - 2023 ", the ... streptococcus (GAS) nucleic acid (NA) test products market was valued ... expand at a CAGR of 11.6% from 2015 to 2023 ...
(Date:5/6/2016)... 2016 Recent studies show that patients no ... medication when treating certain types of pain. With the ... can go right to the source instead of masking ... organization, provides physician training about the benefits of regenerative ... find physicians across the United States ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... most recent release, Clinical Studio Version 4.1, greatly improves performance of the platform. ... where protocols often generate tremendous volumes of data to be collected on a ...
Breaking Biology Technology:
(Date:3/9/2016)... PALM BEACH GARDENS, Fla. , March 9, ... of identity management authentication and enrollment solutions, today ... proven DigitalPersona ® Altus multi-factor ... enable IT and InfoSec managers to step-up security ... friction.  Washington, DC ...
(Date:3/3/2016)... Calif. , March 3, 2016  FlexTech, a ... the categories of Innovation, Research & Development, Leadership in ... Leadership. This is the 9 th year of ... group of companies and individuals from past years ... based on a pre-described set of criteria, by a ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, ... Plus® to offer Oncimmune,s Early CDT®-Lung, a blood ... detection of lung cancer Early CDT®-Lung test ... individuals. --> Early CDT®-Lung test to its ... --> Oncimmune, a leader in early cancer detection, ...
Breaking Biology News(10 mins):